Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPTX2309 in Healthy Volunteers and Subjects With RA or SLE
NCT06917742Phase 1Recruiting
- Sponsor
- Capstan Therapeutics
- Start
- Apr 2025
- Primary completion
- Nov 2027
- Modality
- Lipid-based Nanoparticles, CAR-T Cells, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of CPTX2309 in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) (4 arms), sponsored by Capstan Therapeutics. Primary endpoints: Number of participants with changes in the safety parameters at 1 year, Number of participants with clinical laboratory assessment abnormalities at 1 year and 7 more. Started Apr 2025; status: recruiting.
02
Drugs
CPTX2309
03
Conditions
rheumatoid arthritis (RA)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06917742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06917742.